ClinicalBiostats

Clinical Trials

See the methods at work.

Statistical analyses of real clinical trials: design, endpoints, results and interpretation, organized by therapeutic area and linked to the methods behind them.

407 trials analyzed so far

Trials that use: Hazard ratio

New to this method? Read the tutorial →

334 results

STELLARIndependent statistical analysis of the phase 3 STELLAR trial of sotatercept plus background PAH therapy versus placebo plus background PAH therapy in pulmonary arterial hypertension, including trial design, endpoints, nonparametric analyses, hazard…Phase 3Results postedn = 324NCT04576988
STRENGTHComplete statistical analysis of the STRENGTH phase 3 trial of Epanova versus corn oil control in high cardiovascular risk patients with hypertriglyceridemia, including trial design, MACE, Cox proportional-hazards analysis, secondary endpoints, safety,…Phase 3Results postedn = 13,078NCT02104817
STROKE-AFIndependent statistical analysis of STROKE-AF (NCT02700945), a randomized trial evaluating atrial fibrillation detection through 12 months with Reveal LINQ insertable cardiac monitoring after recent ischemic stroke of presumed known origin.Phase NAResults postedn = 496NCT02700945
SUNLIGHTIndependent statistical analysis of the phase 3 SUNLIGHT trial of trifluridine/tipiracil with and without bevacizumab in refractory metastatic colorectal cancer, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, and statistical interpretation.Phase 3Results postedn = 492NCT04737187
SWOG 9346Independent statistical analysis of SWOG 9346, a randomized phase 3 trial of intermittent versus continuous hormonal therapy in men with stage IV prostate cancer, including overall survival and 3-month functional outcomes.Phase 3Results postedn = 3,040NCT00002651
SWOG S0777Independent statistical analysis of SWOG S0777 (NCT00644228), a randomized phase 3 trial of lenalidomide and dexamethasone with or without bortezomib in previously untreated multiple myeloma.Phase 3Results postedn = 525NCT00644228
TAILORxIndependent statistical analysis of the TAILORx phase 3 trial, focusing on 5-year disease-free survival, the Cox proportional-hazards model, hazard ratios, confidence intervals, and the trial's noninferiority design.Phase 3Results postedn = 10,273NCT00310180
TALAPRO-2Independent statistical analysis of TALAPRO-2, evaluating talazoparib plus enzalutamide versus placebo plus enzalutamide in mCRPC, with detailed interpretation of radiographic progression-free survival and the trial's survival-analysis methods.Phase 3Results postedn = 1,054NCT03395197
TEAMIndependent statistical analysis of TEAM, the randomized phase 3 trial comparing exemestane with tamoxifen followed by exemestane in postmenopausal patients with receptor-positive breast cancer. Includes disease-free survival, overall survival, time to relapse,…Phase 3Results postedn = 9,779NCT00036270
TECOSComplete statistical analysis of TECOS, the randomized phase 3 study of sitagliptin versus placebo in type 2 diabetes mellitus, including non-inferiority analysis of MACE plus, Cox proportional-hazards methodology, secondary endpoints, safety, and…Phase 3Results postedn = 14,671NCT00790205
TEXTIndependent statistical analysis of TEXT, a randomized phase 3 trial of triptorelin with either exemestane or tamoxifen in premenopausal women with hormone-responsive breast cancer, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank…Phase 3Results postedn = 2,672NCT00066703
TH3RESAIndependent statistical analysis of TH3RESA, a randomized phase 3 trial of trastuzumab emtansine versus treatment of physician's choice in participants with HER2-positive breast cancer who had received at least two prior HER2-directed…Phase 3Results postedn = 602NCT01419197
THALESComplete statistical analysis of the phase 3 THALES trial of ticagrelor versus placebo in acute ischaemic stroke and transient ischaemic attack, including trial design, endpoints, Cox and logistic regression methods, efficacy results,…Phase 3Results postedn = 11,016NCT03354429
THEMISIndependent statistical analysis of THEMIS, a randomized phase 3 trial of ticagrelor 60 mg versus placebo in patients with type 2 diabetes mellitus, including time-to-event methods, hazard ratios, confidence intervals, safety analyses,…Phase 3Results postedn = 19,271NCT01991795
THORComplete statistical analysis of the phase 3 THOR trial of erdafitinib in participants with advanced urothelial cancer and selected FGFR gene aberrations, including overall survival, trial design, statistical methodology, and interpretation.Phase 3Results postedn = 629NCT03390504
TITANIndependent statistical analysis of TITAN (NCT02489318), a randomized phase 3 trial of apalutamide plus androgen deprivation therapy versus androgen deprivation therapy in participants with metastatic hormone-sensitive prostate cancer.Phase 3Results postedn = 1,052NCT02489318
ToGAIndependent statistical analysis of the ToGA phase 3 trial of trastuzumab plus fluoropyrimidine/cisplatin versus fluoropyrimidine/cisplatin alone in patients with HER2-positive advanced gastric cancer, including survival, response, statistical methods, interpretation, and safety.Phase 3Results postedn = 584NCT01041404
TOPAZ-1Independent statistical analysis of TOPAZ-1, evaluating durvalumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin in advanced biliary tract cancer, including survival endpoints, response, statistical methods, and interpretation.Phase 3Results postedn = 810NCT03875235
TRA 2P-TIMI 50Independent statistical analysis of TRA 2P-TIMI 50 (NCT00526474), including randomized trial design, time-to-event endpoints, Cox proportional-hazards methods, efficacy results, bleeding outcomes, post-hoc analyses, and statistical interpretation.Phase 3Results postedn = 26,449NCT00526474
TRITON3Independent statistical analysis of TRITON3, a randomized phase 3 trial of rucaparib versus physician's choice of therapy in metastatic castration-resistant prostate cancer with BRCA or ATM alterations.Phase 3Results postedn = 405NCT02975934
TROPiCS-02Independent statistical analysis of TROPiCS-02, a randomized phase 3 trial of sacituzumab govitecan-hziy versus treatment of physician's choice in participants with HR+/HER2- metastatic breast cancer.Phase 3Results postedn = 543NCT03901339
TROPiCS-04Independent statistical analysis of TROPiCS-04, a randomized phase 3 trial of sacituzumab govitecan versus physician's choice of treatment in locally advanced or metastatic unresectable urothelial cancer.Phase 3Results postedn = 711NCT04527991
TROPION-Breast01Independent statistical analysis of TROPION-Breast01, evaluating Dato-DXd versus investigator's choice of chemotherapy in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer.Phase 3Results postedn = 732NCT05104866
TULIPIndependent statistical analysis of the phase 3 TULIP trial of (vic-)trastuzumab duocarmazine versus physician's choice in participants with HER2-positive locally advanced or metastatic breast cancer, including progression-free survival, overall survival, response, quality…Phase 3Results postedn = 437NCT03262935
VADTIndependent statistical analysis of VADT (NCT00032487), evaluating intensive versus standard glycemic control in type 2 diabetes, with a focus on major macrovascular events, hazard ratios, log-rank testing, confidence intervals, and equivalence testing.Phase 3Results postedn = 1,791NCT00032487
VELIAIndependent statistical analysis of the VELIA phase 3 trial of veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage III or IV high-grade serous epithelial…Phase 3Results postedn = 1,140NCT02470585
VELOURIndependent statistical analysis of the phase 3 VELOUR trial of aflibercept plus FOLFIRI versus placebo plus FOLFIRI in metastatic colorectal cancer after failure of an oxaliplatin-based regimen, including trial design, survival analysis,…Phase 3Results postedn = 1,226NCT00561470
VESALIUS-CVComplete statistical analysis of VESALIUS-CV, evaluating evolocumab versus placebo in patients at high cardiovascular risk without prior myocardial infarction or stroke. Includes trial design, time-to-event endpoints, hazard ratios, confidence intervals, statistical methodology,…Phase 3Results postedn = 12,301NCT03872401
VIALE-AIndependent statistical analysis of the phase 3 VIALE-A trial of venetoclax plus azacitidine versus azacitidine in treatment-naive participants with acute myeloid leukemia who are ineligible for standard induction therapy.Phase 3Results postedn = 443NCT02993523
VICTORIAIndependent statistical analysis of the VICTORIA phase 3 trial of vericiguat versus placebo in participants with heart failure with reduced ejection fraction, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, safety,…Phase 3Results postedn = 5,050NCT02861534
VISIONIndependent statistical analysis of the VISION phase 3 trial of 177Lu-PSMA-617 plus best supportive/best standard of care in metastatic castrate-resistant prostate cancer, including randomized design, time-to-event endpoints, hazard ratios, response analyses, safety,…Phase 3Results postedn = 861NCT03511664
VOICEIndependent statistical analysis of the VOICE phase 2 trial of tenofovir 1% gel, oral tenofovir disoproxil fumarate, and emtricitabine/tenofovir disoproxil fumarate for prevention of HIV infection in women.Phase 2Results postedn = 5,029NCT00705679
VOYAGER PADA detailed independent statistical analysis of VOYAGER PAD, the randomized phase 3 trial of rivaroxaban plus aspirin versus placebo plus aspirin in symptomatic peripheral artery disease undergoing lower-extremity peripheral revascularization.Phase 3Results postedn = 6,564NCT02504216
ZUMA-7Independent statistical analysis of ZUMA-7, the randomized phase 3 trial of axicabtagene ciloleucel versus standard of care therapy in relapsed/refractory diffuse large B-cell lymphoma, including event-free survival, response, overall survival, quality of…Phase 3Results postedn = 359NCT03391466